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Abstract
Background: Tuberculosis contributes significantly to morbidity and mortality among HIV-infected children in sub-
Saharan Africa. Isoniazid prophylaxis can reduce tuberculosis incidence in this population. However, for the treatment
to be effective, adherence to the medication must be optimized. We investigated adherence to isoniazid prophylaxis
administered daily, compared to three times a week, and predictors of adherence amongst HIV-infected children.
Methods: We investigated adherence to study medication in a two centre, randomized trial comparing daily to three
times a week dosing of isoniazid. The study was conducted at two tertiary paediatric care centres in Cape Town, South
Africa. Over a 5 year period, we followed 324 HIV-infected children aged ≥ 8 weeks. Adherence information based on
pill counts was available for 276 children. Percentage adherence was calculated by counting the number of pills returned.
Adherence ≥ 90% was considered to be optimal. Analysis was done using summary and repeated measures, comparing
adherence to the two dosing schedules. Mean percentage adherence (per child during follow-up time) was used to
compare the mean of each group as well as the proportion of children achieving an adherence of ≥ 90% in each group.
For repeated measures, percentage adherence (per child per visit) was dichotomized at 90%. A logistic regression model
with generalized estimating equations, to account for within-individual correlation, was used to evaluate the impact of
the dosing schedule. Adjustments were made for potential confounders and we assessed potential baseline and time-
varying adherence determinants.
Results: The overall adherence to isoniazid was excellent, with a mean adherence of 94.7% (95% confidence interval
[CI] 93.5-95.9); similar mean adherence was achieved by the group taking daily medication (93.8%; 95% CI 92.1-95.6) and
by the three times a week group (95.5%; 95% CI 93.8-97.2). Two-hundred and seventeen (78.6%) children achieved a
mean adherence of ≥ 90%. Adherence was similar for daily and three times a week dosing schedules in univariate (odds
ratio [OR] 0.88; 95% CI 0.66-1.17; P = 0.38) and multivariate (adjusted OR 0.85; 95% CI 0.64-1.11; P = 0.23) models.
Children from overcrowded homes were less adherent (adjusted OR 0.71; 95% CI 0.54-0.95; P = 0.02). Age at study visit
was predictive of adherence, with better adherence achieved in children older than 4 years (adjusted OR 1.96; 95% CI
1.16-3.32; P = 0.01).
Conclusion: Adherence to isoniazid was excellent regardless of the dosing schedule used. Intermittent dosing of
isoniazid prophylaxis can be considered as an alternative to daily dosing, without compromising adherence or efficacy.
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Background
In 2007, 90% of the estimated 2.0 million HIV-infected
children worldwide lived in sub-Saharan Africa, a reflec-
tion of the HIV epidemic in adults of the same region [1].
Opportunistic infections, especially tuberculosis (TB), are
a major cause of morbidity and mortality amongst these
children [2,3]. Internationally, significant progress has
been made to minimize morbidity and mortality amongst
people living with HIV/AIDS. The benefits of highly active
antiretroviral therapy (HAART), trimethoprim-sulphame-
thoxazole (TMP-SMX) prophylaxis and, more recently,
isoniazid (INH) prophylaxis for preventing TB, have been
proven in adults and children in various settings [4-8].
However, in resource-limited settings these benefits are
rarely realized. Obstacles include cost, interrupted drug
supplies and suboptimal adherence [1,9,10].
To enable all those infected by HIV to benefit from these
life-saving interventions, it is imperative that cost-effec-
tiveness and barriers to adherence be urgently and inno-
vatively addressed. Common barriers to adherence
include complex dosing schedules, toxicity, pill burden
and, in many resource-limited settings, financial cost to
the patient [11,12]. Intermittent dosing schedules can
potentially address these adherence barriers and may
prove cost-saving. Intermittent dosing for the treatment
and prevention of TB has been successfully used for adults
and efficacy has been proven in children [8,13-15]. Even
if the efficacy of a treatment is similar for different dosing
schedules, it is possible that subtle adherence differences
may impact on the feasibility and effectiveness when the
treatment is rolled out on a large scale. To our knowledge,
there have been no randomized controlled trials evaluat-
ing the impact of dosing schedule on adherence to INH
prophylaxis in HIV-infected children.
In a recent placebo-controlled trial evaluating INH proph-
ylaxis for HIV-infected children in Cape Town, South
Africa, INH markedly reduced mortality and TB incidence
with no difference in the efficacy between a daily and an
intermittent dosing schedule [8]. Using the same study
cohort, we describe the overall adherence rates as meas-
ured by pill counts and caregiver self-reports. We investi-
gate the potential differences in adherence between the
two dosing schedules and assess the predictors of adher-
ence.
Methods
Design
We assessed the adherence to study medication in a rand-
omized, placebo-controlled trial evaluating the impact of
INH therapy on TB incidence and mortality among HIV-
infected children. The trial had a factorial design with two
levels of randomization: participants were randomized to
either INH or placebo, which were given either daily or
three times a week. TMP-SMX prophylaxis was adminis-
tered on the same dosing schedule as INH/placebo. Enrol-
ment for the study began in December 2002 at two tertiary
paediatric care centres in Cape Town, South Africa. Enrol-
ment continued until March 2005. The initial funding
allowed for up to 2 years of follow-up. Subject to the avail-
ability of funding, further follow-up (and the continua-
tion of INH) was to be considered by the study data and
safety monitoring board (DSMB), based on interim anal-
yses of the main outcomes, provided that caregiver con-
sent and further ethics committee approval was obtained.
As reported previously, interim analysis of the main out-
comes showed a significant early survival benefit for chil-
dren receiving INH [8]. On the recommendation of the
DSMB, the placebo arm was discontinued on 17 May
2004. With caregiver consent and approval by the relevant
ethics committees, children who had been randomized to
receive placebo were then commenced on INH, either
daily or three times a week, and the follow-up time was
prolonged until a further assessment by the DSMB. The
trial continued to assess the potential differences in effi-
cacy, toxicity and adherence between the groups rand-
omized to daily or three times a week INH and TMP-SMX.
The final DSMB recommendation was to discontinue INH
for all patients at the earliest study visit after 31 December
2007.
Setting and participants
The study was conducted at the Red Cross War Memorial
Children's Hospital (University of Cape Town) and Tyger-
berg Children's Hospital (Stellenbosch University), two
tertiary paediatric care centres in Cape Town, South Africa.
HIV-infected children older than 8 weeks of age were
recruited from inpatient- and outpatient settings at the
two study sites, as well as from nearby referral hospitals
and clinics. HIV status was confirmed at enrolment by
polymerase chain reaction (Amplicore HIV-1, Roche
Diagnostic Systems) in children aged 15 months or
younger and by two enzyme linked immunosorbent
assays (Abbot AxSYM HIV antibody/antigen ELISA) in
older children. The inclusion and exclusion criteria have
already been described [8] and included residence in the
Cape Town Metropolitan area with access to public or
other transport. Written informed consent was obtained
from a parent or legal guardian. Randomization proce-
dures and blinding of INH/placebo allocation have
already been described [8]. Researchers collected socio-
demographic, clinical and laboratory data at enrolment
and at scheduled follow-up visits. Study pharmacists dis-
pensed the study drugs at each follow-up visit. The chil-
dren were seen every 4 weeks for the first 6 months, every
6 weeks for the next 6 months and then every 2-3 months,
depending on medical and social circumstances. At the
start of the study, HAART was not widely available to
South African children, but it had been accessed for someBMC Medicine 2009, 7:67 http://www.biomedcentral.com/1741-7015/7/67
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through charitable donations or participation in pharma-
ceutical trials. During the study period, the South African
government initiated a public sector anti-retroviral pro-
gramme and all study participants who qualified on med-
ical and social criteria (as defined by national guidelines)
were commenced on HAART.
Ethical approval and monitoring
A data and safety monitoring board, comprising interna-
tional and South African experts, was established to
review the safety and progress of the study based on 3 to
6-monthly interim data analyses. The study was con-
ducted in compliance with the Declaration of Helsinki.
Ethical approval was given by the research and ethics com-
mittees of the Universities of Cape Town and Stellen-
bosch, South Africa. This secondary analysis was also
approved by the Johns Hopkins School of Medicine Insti-
tutional Review Board.
Intervention
Children were randomized to receive INH or placebo
either daily or three times a week (Monday, Wednesday
and Friday). INH tablets (100 mg, Be-Tabs Pharmaceuti-
cals, Johannesburg, South Africa) were given at a dose of
10 mg/kg with range of 8-12 mg/kg depending on
whether half or quarter tablets were required. INH was not
given in syrup form as this has potential long-term toxicity
from additives such as chloroform, requires reconstitu-
tion by a pharmacist and, due to the higher cost, is not
readily available in resource-limited settings. Placebo tab-
lets were manufactured to look identical to INH tablets.
TMP-SMX was administered according to the same dosing
schedule as INH/placebo, at a dosage of 5 mg/kg of the tri-
methoprim component.
Adherence monitoring and support
All caregivers were issued monthly treatment diaries as an
aid to adherence. The diaries were provided in English,
Afrikaans or isiXhosa, depending on caregiver preference.
Caregivers were requested to tick 'yes' or 'no' for each day
of the month, indicating whether or not medication was
administered on that day. Multiple diaries were supplied
as needed. Space was provided for notes detailing any dif-
ficulties in administering the drugs. Illiterate caregivers
were shown how to tick 'yes' or 'no' for each day medica-
tion was given (Additional file 1). Caregivers were
instructed to return all empty medicine containers and
any medication left over at each visit, along with the com-
pleted diaries. At each visit, caregivers were given the
opportunity to discuss any difficulties regarding medica-
tion administration. Consultations occurred in English,
Afrikaans or isiXhosa, depending on the caregiver's prefer-
ence. To accommodate unforeseen difficulties in attend-
ing visits, up to 1 week's extra supply of study medication
was issued at each visit. Meals and compensation for
travel costs were provided on the scheduled study visits. If
a child missed a scheduled visit, attempts were made to
contact their caregiver. If caregivers were not able to be
contacted by telephone and/or did not return for a
rescheduled visit, community workers contacted them in
person. A minimum of three attempts at contacting car-
egivers was required over a period of 3 months before a
child was declared lost to follow-up.
For the first 11 months of the study adherence was
assessed by caregiver self-report only. Caregivers were
asked how many doses of medication had been taken in
the previous week, starting from the day before the visit.
From October 2003 to February 2005, both caregiver
reports and pill counts were used to measure adherence.
Adherence monitoring by pill counts continued until
March 2008, when the last study participant discontinued
INH. At each scheduled study visit, study pharmacists cal-
culated the number of tablets that were presumably
administered to the child by subtracting the number of
pills returned from those dispensed. This number was
then expressed as a percentage of the number of tablets
that should have been given to the child. Study team phar-
macists, doctors and/or nurses counselled all caregivers
on adherence at the regular study visits and provided
immediate feedback on pill count calculations.
Statistical analysis
Outcome measures and predictors
We used various methods to explore potential adherence
differences between dosing schedules. Summary measures
of adherence were used to assess overall adherence and for
simple comparisons of adherence between the groups.
Mean adherence per child over follow-up time was com-
pared between groups using a two-sample t-test with Sat-
terthwaite's modified degrees of freedom. The proportion
of children achieving mean adherence ≥ 90% was also
compared between groups. Although completing 80% of
prescribed doses is the conventional standard for adher-
ence assessment in trials of TB prophylaxis [16], both self-
report measures and clinic-based pill counts have been
reported to overestimate adherence [17-19]. Furthermore,
adherence of 95% is considered optimal in the context of
HAART [20], although a cut off of 90% is often used.
Given our study population, we chose a more conserva-
tive cut-off of 90% to indicate adherence to INH. Car-
egiver self-report and pill count determined adherence
measures were analysed separately for group effect. Car-
egiver reported adherence was transformed into a percent-
age adherence by dividing the reported number of doses
given by the number of doses that should have been given
in the previous week. We explored agreement between
caregiver report and pill counts using binary indicators cut
at 90%.
The effect of time on mean adherence was visualized by
comparing mean adherence per year between four yearBMC Medicine 2009, 7:67 http://www.biomedcentral.com/1741-7015/7/67
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categories: 0-12 months; 12-24 months; 24-36 months;
and > 36 months on study. Mean adherence per child per
year was used to calculate overall mean adherence per
year.
Death and lost-to-follow up might represent non-adher-
ence in the extreme and are not accounted for by pill
counts or self-report. We therefore compared these
between groups using the chi squared statistic with
Fisher's exact test. We also compared the mean number of
admissions and the number of children who were diag-
nosed with TB between the groups.
As more pill return measures than caregiver self-reports
were available, and over a longer period of time, we chose
percentage adherence to INH/placebo as determined by
pill counts as our main outcome measure. We chose to
dichotomize percentage adherence in order to use logistic
regression as assumptions for linear regression did not
hold. Our primary independent variable was the dosing
schedule (daily versus three times per week), hereafter
referred to as the prophylaxis group. In order to allow
both baseline and time-varying covariates to be explored
as potential determinants of adherence, we applied a
binary logistic regression model with generalized estimat-
ing equations (GEE) and robust variance estimation to
account for the within-patient correlation of adherence
measures. An independence working correlation was
assumed [21].
Characteristics assessed at enrolment included the proph-
ylaxis group (daily or three times a week), study site, gen-
der, availability of amenities and the number of
individuals per household. We chose to model child age
as dynamic, using age at pill count visit rather than age on
enrolment. Other potential time-varying adherence deter-
minants (indicating status at time of adherence measure-
ment) were: study drug (INH or placebo); severity of
disease (HIV clinical and immunological staging); time
on study; and concurrent use of HAART. We categorized
HIV disease severity according to the Centers for Disease
Control and Prevention (CDC) clinical and immunologi-
cal staging criteria; categories N and A (mild clinical dis-
ease) were combined for the analysis, as there were only a
few children in category N. We fitted locally weighted scat-
terplot smoothing (lowess) models for each continuous
predictor against the logarithm of adherence to establish
the general form of the relation. The age of a child was cat-
egorized as: (1) less than 1 year; (2) 1-4 years; or (3) over
4 years. Time on study was dichotomized at 1 year. The
number of individuals per household was dichotomized
at five (median number per household). Collinearity was
checked with variance inflation factors. Univariate logistic
regression with GEE was used to assess total effects of var-
iables on adherence. Variables that were associated with
adherence at a level of P < 0.1 were included for multivar-
iate analysis. Variables lacking significant association with
the outcome, which have previously been identified as
independent predictors of adherence in the published lit-
erature, were also retained in the model (HIV clinical and
immunological disease severity; concurrent use of
HAART; gender; length of time on study). The study site
was also forced in the model to adjust for unmeasured
confounders between sites. Potential interactions between
the prophylaxis group and all other covariates were
explored. The model fit was further assessed using
Akaike's information criteria. The statistical unit for the
longitudinal analysis is the child; odds ratios < 1 indicate
worse adherence. All P-values are two-tailed. Data were
analysed using Stata statistical software, version 10 (Stata)
[22].
Sample size
We present the a priori sample size calculations based on
the primary objectives of the overall study. For the pri-
mary outcomes of the two levels of the study - namely
mortality comparing INH to placebo (superiority) and
mortality comparing daily to three times per week TMP-
SMX (equivalence), sample sizes of 216 per arm (432 chil-
dren overall) - was calculated to achieve power ≥ 80%,
allowing for a 10% drop out. Using a survival analysis
approach, a sample size of 196 children per arm would
have allowed a 0.05 level one-sided log-rank test to have
80% power to detect the difference between a placebo
mortality proportion at time t of 0.100 and an INH mor-
tality proportion at time t of 0.050 (constant hazard ratio
of 0.769), assuming no drop outs before time t. With 200
subjects in each group, the lower limit of the observed
one-sided 95% confidence interval was expected to exceed
-0.1 (a difference in mortality of less than 10%) with 95%
power when the standard survival proportion was 0.9 and
the test expected survival proportion was 0.9.
The a priori study design did not include a sample size cal-
culation for this secondary analysis. The sample size (n =
276) for our main analysis was necessarily limited to chil-
dren whose caregivers provided medication returns from
which we could calculate the pill counts. Based on previ-
ous literature, we expected adherence rates of 60%-80% to
daily INH. We chose a priori to define an adherence differ-
ence of ≥ 10% as clinically significant. With a sample size
of 276 (n1 = 129, n2 = 148), we have 100% power to
detect a 10% difference between a mean percentage
adherence of 70 and a mean percentage adherence of 80.
(Additional file 2)
Results
Study population
A total of 339 children were enrolled in the study. Fifteen
were excluded from the study soon after enrolment (10
tested HIV-negative on confirmatory tests and five were
lost to follow-up within 1 month). For the main analysisBMC Medicine 2009, 7:67 http://www.biomedcentral.com/1741-7015/7/67
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of adherence using pill count measures, we further
excluded 30 who were censored from the study before pill
count based adherence monitoring started in October
2003 (Figure 1). Of the 294 children who were uncen-
sored by October 2003, adherence percentage calculations
were available for 276; the baseline characteristics of these
children are shown in Table 1. About half of the children
were boys. The median age at enrolment was 26 months,
with 25% of the children younger than 12 months. Only
three were older than 10 years when they joined the study.
Most had symptomatic HIV disease, either CDC clinical
category B or C. Similarly, just over 70% were classified as
having moderate to severe immunological impairment
(CD4 count of < 25% total lymphocyte count). Twenty-
eight (10%) were on HAART at enrolment and a further
170 (61.6%) started HAART during the study. A large pro-
portion had relatively poor socio-economic circum-
stances. Just under half of the children did not live in brick
houses but in temporary dwellings. Although electricity
was available to the majority, 52.2% did not have tap
water in their house and 56% did not have ready access to
a flush toilet. The median number of people sharing a
house was five, with 35.6% of the children coming from
households containing more than five people.
Ten children had measurements for caregiver self-reported
adherence only; they were all censored before pill count
measures were introduced. Their baseline characteristics
were as follows: seven received daily prophylaxis; the
median age was 11 months; and there were four boys. All
10 children were classified as either CDC clinical stage B
or C; 8 were either CDC immune category 2 or 3. Only
three received HAART before censoring. (Two more vol-
untarily withdrew from the study as they were due to start
HAART, two were lost to follow up within three months
and one child relocated. Four children died; three of these
were on placebo at the time). The same number had
access to water and electricity (6); the median number of
individuals per household was 5. Four children lived in
brick houses and the same number had access to a flush
toilet. Half of the children were on placebo; equal num-
bers came from each study site.
Follow-up, attrition and disease
Over 5 years from December 2002 to March 2008, the
mean follow-up time was 25.3 months (standard devia-
tion [SD] 16.3 months). The average time receiving INH
prophylaxis was 22.5 months (SD 16.3 months); 75% of
children received 12 or more months of INH. Of the 291
children who should have been receiving INH (that is,
excluding children randomized to placebo and censored
prior to unblinding), only 35 (12%) did not complete 6
months of INH: 25 had died, four were lost to follow-up
and six had withdrawn from the study. Three of these chil-
dren had relocated. Eighteen of the 35 had been allocated
to daily prophylaxis.
Overall, 28 (8.6%) of the 324 children were lost to follow-
up during the study period (mean follow-up time 18
months, similar between groups P = 0.81); the majority of
these (75%) were followed for at least 1 year. Numbers of
deaths and withdrawals were also similar in both study
groups. Fifty-three children died, 29 of whom (55%) were
in the daily group (P = 0.45). Thirty-eight were withdrawn
from the study; 20 of these were in the daily group (P =
0.73). Two-thirds of the withdrawals were due to logistical
difficulties for the caregiver. The most often cited reason
was the relocation of the family (16 of 38, 42%); other
reasons for withdrawal included severe illness (2) and
decision to stop once HAART commenced (8). The mean
number of hospital admissions was 1.4 in both groups (P
= 0.83). Twenty-two of the 41 children who were diag-
nosed with TB were taking daily prophylaxis (P = 0.53).
Two of these children were diagnosed with multi-drug
resistant TB; both were on daily prophylaxis and had
mean adherence below 90%.
Adherence measures and effects of covariates
Adherence measured by caregiver self-report
Reports were available for 190 of the children. Ninety-six
(51%) were in the daily group. The overall mean adher-
ence was high (94.67%; 95% CI 91.5-97.8) and similar in
both groups (daily group adherence 94.69%; 95%CI 92.4-
97 and three times a week group adherence 94.67%; 95%
CI 88.6-100.7). Similar proportions of children achieved
adherence of 90% or higher in the daily (0.81; 95% CI
0.73-0.89) and in the three times per week group (0.80;
95%CI 0.72-0.88).
Agreement between caregiver self-report and pill counts
Caregiver self-reports were available for 316 pill count vis-
its (190 children). The numbers of visits at which children
were classified as having adhered (achieving adherence ≥
90%) by pill counts compared to self-reports is shown in
Table 2. A statistically significant chi squared was
obtained for 2 × 2 comparison of adherence classifications
based on the two measures (P = 0.002, Fisher's exact test).
We calculated kappa statistics, comparing the adherence
classification (adherent, ≥ 90%; non-adherent, < 90%)
between the two measures per child per visit, as well as the
overall adherence classification (mean adherence per
child over total study time; classified as adherent, ≥ 90%
or non-adherent, < 90%) The two measures had an
observed agreement of 76%, kappa = 0.18 for individual
measurements (per child per visit); a comparison of the
overall adherence gave a slightly lower kappa statistic of
0.1. A summary of the adherence classification based on
all available measures is shown in Table 3.
Adherence measured by pill counts
Children attended pill count visits an average of 18 times.
Similar numbers of pill count visits were recorded for chil-
dren receiving daily (mean = 18.7 visits; 95% CI 16.8-BMC Medicine 2009, 7:67 http://www.biomedcentral.com/1741-7015/7/67
Page 6 of 13
(page number not for citation purposes)
Table 1: Baseline comparison of children randomized to daily and three times a week dosing schedule.
Baseline characteristics Daily
(n = 128)
Three times a week (n = 148) Total
(n = 276)
P* Value
Sex (%)
Male 57.0 55.4 56.3 0.81
Age (months) 0.45
Median 29.7 21.8 25.9
(IQR) (13.1 to 47.7) (10.2 to 52.6) (11.9 to 51.0)
Age (years; %) 0.50
< 1 year 23.4 26.4 25.0
1-4 years 51.6 44.6 47.8
> 4 years 25.0 29.0 27.1
Study drug (%) 0.39
Placebo 35.2 40.5 38.0
Isoniazid 64.8 59.5 62.1
Site (%) 0.55
RCCH 52.3 48.0 50.0
TCH 47.7 52.0 50.0
CDC clinical stage (%) 0.95
N or A 14.8 13.5 14.1
B6 5 . 6 6 6 . 96 6 . 3
C1 9 . 5 1 9 . 6 1 9 . 6
CDC immune stage (%) 0.09
12 2 . 7 3 4 . 52 9 . 0
24 6 . 1 3 7 . 24 1 . 3
33 1 . 2 2 8 . 42 9 . 7
On HAART at randomization (%) 10.9 9.5 10.1 0.7
Started HAART during study (%) 64.8 58.8 61.6 0.32
No tap water in house (%) 50.0 53.7 52.2 0.63
No electricity in house (%) 16.5 23.7 20.3 0.18
No flush toilet in house (%) 55.1 56.8 56.0 0.81
Not a brick house (%) 41.7 45.6 43.8 0.54
Number of people living in house 0.5
Med 5 5 5
(IQR) (3 to 6) (4 to 6.5) (3 to 6)
Number of people in house (%) 0.31
≤ 56 7 . 7 6 1 . 5 6 4 . 4
> 5 32.3 38.5 35.6
Figures are medians (interquartile range) for continuous variables and percentage of children for categorical variables.
* P-values from Fisher's exact test for categorical data or two-sample Wilcoxon rank-sum (Mann-Whitney) test for continuous data
RCCH = Red Cross War Memorial Children's Hospital; TCH = Tygerberg Children's Hospital; CDC = Centers for Disease Control and 
Prevention; HAART = highly active antiretroviral therapy.BMC Medicine 2009, 7:67 http://www.biomedcentral.com/1741-7015/7/67
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20.3) and three times a week prophylaxis (mean = 18.5
visits; 95% CI 17.0-19.9). Overall mean adherence for the
study cohort was 94.7% (95% CI 93.5-95.9); 78.6% (217
children) achieved a mean adherence of greater or equal
to 90%. A mean adherence of 93.8% was achieved by the
daily prophylaxis group (95% CI 92.1-95.6). The three
times a week prophylaxis group obtained a similar mean
adherence of 95.5% (95% CI 93.8-97.2) The proportion
of children considered to be adherent was also similar
between the groups: 78% of those receiving daily prophy-
laxis had a mean adherence measurement of at or above
90% (95% CI 71-85) compared to 79% of those in the
three times a week group (95% CI 72-86). Figure 2 com-
pares the average percentage adherence between the two
prophylaxis groups.
Mean adherence measures per year of follow-up and the
number of children contributing to each estimate are
shown in Figure 3.
In univariate logistic regression, the prophylaxis group
was not associated with adherence greater than or equal to
90% (OR 0.88; 95% CI 0.66-1.17; P = 0.38). Age at study
visit was significantly associated with adherence: com-
pared to children of less than 1 year of age, 1-4 year olds
were less likely to be adherent (OR 0.77; 95% CI 0.6-0.98;
P = 0.03) and children over 4 years were more likely to be
adherent (OR 1.4; 95% CI 1.09-1.8; P = 0.008). House-
hold size and the duration of time that a child had been
in the study were associated with adherence at the α = 0.1
level. Children who had been in follow-up for more than
1 year were 20% less likely to be adherent than those who
had been more recently enrolled (OR 0.82; 95% CI 0.67-
1.01; P = 0.06; Table 4). In multivariate regression, only
age at visit and household size were significantly associ-
ated with adherence at the α = 0.05 level after adjusting
for prophylaxis group, site, sex, time on study, concurrent
use of HAART and disease staging (both CDC immune
and clinical staging). Children older than 4 years were
almost twice as likely to be adherent as children aged less
than 1 year (adjusted OR 1.96; 95% CI 1.16-3.32; P =
0.01). In the multivariate regression model, children aged
1-4 years were not significantly more or less likely to be
adherent than children aged less than 1 year (P = 0.11).
Adherence was significantly worse in those from larger
households (adjusted OR 0.71; 95% CI 0.54-0.95; P =
0.02). After adjusting for other characteristics, children
who had been in follow-up for longer than a year were
still less likely to be adherent compared to those with less
follow-up time, but this failed to reach statistical signifi-
cance (adjusted OR 0.83; 95% CI 0.66-1.05; P = 0.12) No
significant interactions were found between prophylaxis
group and other covariates.
Discussion
Daily INH prophylaxis showed no adherence benefit over
the three times per week regimen in our study. As reported
previously, the efficacy of the two dosing schedules was
Flow of participants through trial Figure 1
Flow of participants through trial.
Children randomised 
(n=339)
Tygerberg Children’s Hospital (n=164)  Red Cross Children’s Hospital (n=175) 
Allocated to
Daily
(n=91)
Allocated to
Thrice Weekly 
(n=84)
Allocated to
Daily
(n=80)
Allocated to
Thrice Weekly 
(n=84)
Censored prior to 
October 2003
(n=9):
Reasons:
Did not have HIV 
(n=0)
 Died (n=7) 
 Lost to follow up 
(n=2)
 Withdrew (n=0) 
Censored prior to 
October 2003 
(n=6):
Reasons:
Did not have HIV 
(n=2)
 Died (n=3) 
 Lost to follow up   
(n=0)
 Withdrew (n=1) 
Censored prior to 
October 2003
(n=16):
Reasons:
Did not have HIV 
(n=5)
 Died (n=5) 
 Lost to follow up 
(n=5)
 Withdrew (n=1) 
Censored prior to 
October 2003
(n=14):
Reasons:
Did not have HIV 
(n=3)
 Died (n=6) 
 Lost to follow up 
(n=3)
 Withdrew (n=2) 
No adherence 
measures (n=1) 
No adherence 
measures (n=3) 
No adherence 
measures (n=4) 
No adherence 
measures (n=10) 
Analyzed (n=77)  Analyzed (n=61)  Analyzed (n=71)  Analyzed (n=67) 
Table 2: Agreement between pill counts and caregiver self-report classification of adherent (adherence ≥ 90%) or non-adherent 
(adherence < 90%).
Adherent by pill count Non-adherent by pill count Total
Adherent by self-report 225 (71%) 56(18%) 281
Non-adherent by self-report 19(6%) 16(5%) 35
Total 244 72 316
Numbers are expressed as percentages of total number of visits (n = 316); adherence estimates are based on a single visit evaluation and limited to 
visits where both measures were used.
* Chi squared 11.76, Fisher's exact test, p = 0.002BMC Medicine 2009, 7:67 http://www.biomedcentral.com/1741-7015/7/67
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equivalent, with both groups experiencing a marked
reduction in mortality and TB incidence when on INH as
compared to placebo [8]. Furthermore, no toxicity differ-
ence was found between the two groups (unpublished
data). In our cohort, three times a week INH prophylaxis
was therefore not only highly efficacious in reducing mor-
tality and TB in HIV-infected children, but also as easily
adhered to and tolerated as daily INH. The use of isoni-
azid as TB prophylaxis in HIV-infected adults, after the
exclusion of active TB, is recommended as part of the
World Health Organization's Stop TB strategy [23]. INH
prophylaxis is also recommended for children younger
than 5 years with proven or suspected latent TB, irrespec-
tive of HIV status, although experts advise that HIV-
infected children of all ages would benefit [24,25]. Yet the
implementation of these measures has been slow, limited
by concerns regarding the emergence of TB resistance as
well as by economic and health system constraints [1]. For
HIV-infected children in whom active TB has been
excluded, an intermittent dosing schedule of INH proph-
ylaxis would be cheaper and potentially easier to admin-
ister than daily INH. This could, in part, help to address
the latter concerns.
Overall adherence to INH among our cohort of children
was excellent, with the majority achieving a mean adher-
ence of ≥ 90%. This is in keeping with population HAART
adherence rates found in HIV-infected adults and children
from similar resource-limited settings [26-28]. There is no
gold standard for adherence [29]. As with adherence to
HAART, comparing estimates of adherence to TB prophy-
laxis between studies is complicated by varying defini-
tions of adherence and the use of different adherence
tools [11,12]. Traditionally, completion rates (based on
taking > 80% of the prescribed doses) have been used to
describe adherence to TB prophylaxis [16]. In our study,
88% of children prescribed INH completed a minimum
of 6 months of prophylaxis. Only 47.1% of South African
HIV-infected adults completed 6 months INH prophy-
laxis in an operational setting [30], compared to 76% of
adults in an Ugandan study [31]. In seminal pre-HIV stud-
ies of INH prophylaxis, approximately 70% of Alaskan
children were considered to be adherent to study medica-
tion based on completion rates [32]. In one prospective
and one retrospective study evaluating adherence to INH
prophylaxis in operational settings in Cape Town, South
Africa, only 15% and 27% respectively of the children
completed 5-6 months of INH [33,34]. The majority of
Table 3: Numbers of children classified as adherent (adherence ≥ 90%) or non-adherent (adherence < 90%) by adherence measure 
used.
Adherence measure Adherent (%) Non-adherent (%) Total
Pill counts 217(78.6%) 59(21.4%) 276
Caregiver self-report 153(80.5%) 37(19.5%) 190
Percentages calculated by adherence measure; adherence estimates based on mean adherence per child over follow-up time.
Average percentage adherence in HIV-infected children com- paring three times a week isoniazid to daily treatment calcu- lated from announced pill counts Figure 2
Average percentage adherence in HIV-infected chil-
dren comparing three times a week isoniazid to daily 
treatment calculated from announced pill counts.
Mean adherence to isoniazid prophylaxis per year of follow- up time Figure 3
Mean adherence to isoniazid prophylaxis per year of 
follow-up time.BMC Medicine 2009, 7:67 http://www.biomedcentral.com/1741-7015/7/67
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Table 4: Odds ratios for baseline and time-varying predictors of adherence ≥ 90%.
Baseline characteristics Univariate model
OR (95% CI) P*
Multivariate model†
AOR (95% CI) P*
Dosing schedule (prophylaxis group) Three times a week 1 1
Daily 0.88 (0.66, 1.17) 0.38 0.85 (0.64, 1.11) 0.23
Study site RCCH 1 1
TCH 1.25 (0.95, 1.67) 0.11 1.12 (0.82, 1.54) 0.46
Gender Male 1 1
Female 1.17 (0.87, 1.57) 0.30 1.11 (0.82, 1.50) 0.51
Number of individuals in house ≤ 51 1
> 5 0.77 (0.57 1.02) 0.07 0.71 (0.54, 0.95) 0.02
Brick house No 1 -
Yes 0.98 (0.73, 1.30) 0.87
Tap water in house No 1 -
Yes 1.07 (0.80, 1.43) 0.64
Flush toilet in house No 1 -
Yes 1.08 (0.82, 1.44) 0.57
Electricity in house No 1 -
Yes 0.93 (0.61, 1.41) 0.74
Time-varying characteristics
Age at visit < 1 year 1 1
1-4 years 0.77 (0.6, 0.98) 0.03 1.47 (0.91, 2.37) 0.11
> 4 years 1.40 (1.09, 1.80) 0.008 1.96 (1.16, 3.32) 0.012
Time on study at visit < 1 year 1 1
≥ 1 year 0.82 (0.67, 1.01) 0.06 0.83 (0.66, 1.05) 0.12
CDC clinical N or A 1 1
stage at visit B 1.11 (0.85, 1.46) 0.44 0.85 (0.54, 1.34) 0.48
C 0.86 (0.65, 1.14) 0.30 0.71 (0.43, 1.16) 0.17
CDC immune 1 1 1
Stage at visit 2 0.94 (0.73, 1.20) 0.62 0.96 (0.69, 1.34) 0.83
3 1.02 (0.79, 1.32) 0.86 1.00 (0.70, 1.44) 0.99
Study drug at visit Placebo 1 -
Isoniazid 1.02 (0.73, 1.43) 0.91 -
On HAART at visit No 1 1
Yes 1.14 (0.89, 1.45) 0.30 1.08 (0.82, 1.43) 0.56
† Adjusted for group, site, sex, number of people in house, age at visit, concurrent HAART, CDC immune stage at visit, CDC clinical stage at visit, 
time on study at visit. Two patients excluded from multivariate model due to missing information on number of people in the house and CDC 
immune staging at follow up.
OR = odds ratio; AOR = adjusted OR; CI = confidence interval; RCCH = Red Cross War Memorial Children's Hospital; TCH = Tygerberg 
Children's Hospital; CDC = Centers for Disease Control and Prevention; HAART = highly active antiretroviral therapy; * P values from Wald testsBMC Medicine 2009, 7:67 http://www.biomedcentral.com/1741-7015/7/67
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these children had an unknown HIV status or were HIV
negative. Medication completion rates allow for easy doc-
umentation of poor adherence to short-term therapy and
are important for programmatic evaluation. However, its
use in clinical settings is limited as there is no scope for
timely adherence interventions. Our cohort of children
and caregivers were provided with substantial adherence
support. In particular, the adherence measures we used
allowed for immediate feedback and counselling. This
allowed the care providers to focus attention on those
children and caregivers who were struggling and may, at
least in part, explain our high completion rates.
Pill counts may overestimate adherence [17,19]. Other
studies of INH have reported pill count-based adherence
estimates similar to ours. An Australian study of INH
prophylaxis in adolescents recorded a pill count-based
adherence estimate of 91% compared to 79% by urine
testing, 83% by clinic attendance and 66% by medication
event monitoring system [35]. A mean adherence of 85%
was reported in a placebo-controlled trial of INH prophy-
laxis for HIV-infected adults in a setting similar to ours,
based on pill counts. These adherence measures correlated
well with the reports of patient nominated supervisors
[36]. Overestimation of adherence by pill counts is based
on falsely assuming that unreturned pills were ingested by
the patient. Pill dumping, where containers are returned
empty without any medication being taken, is an extreme
example, but patients may also discard only a few of the
remaining tablets prior to returning the container. In
young children, medication doses often have to be
repeated by the caregivers due to vomiting, spitting out of
medicine or spillage. When more medication is provided
than needs to be taken, this can potentially lead to adher-
ence measures of > 100%, even if pill dumping did not
occur [37]. In a Ugandan study of paediatric and adult
adherence to HAART, unannounced home-based pill
counts provided more conservative estimates of adher-
ence than in-clinic announced pill counts (72% of home-
based counts achieved adherence > 95% compared to
94% of in-clinic counts) [18]. As our adherence estimates
were based on announced pill counts and include some
measures above 100%, there was a possible overestima-
tion of adherence. However, the comparison between the
prophylaxis groups remains valid. Furthermore, there was
a high correlation of pill counts and caregiver self-report,
indicating good adherence by multiple measures. A feasi-
bility study of INH prophylaxis in HIV-infected Ugandan
adults similarly found high adherence rates by both pill
counts (82%) and self-report (85%). In the same cohort,
high adherence estimates were also reported by clinic
attendance (81%) and urine testing (79%) [31].
In a recent systematic review of paediatric HAART adher-
ence in low- and middle-income countries, self- or car-
egiver (proxy)-reports were the most frequently used
measures of adherence, providing high estimates of
adherence (79.5-100%) [11]. Although recall and social
desirability bias can result in inflated estimates of adher-
ence, self-report has shown moderate correlation with
virological outcomes of patients on HAART [19]. Self-
report adherence measures were also valid and reliable in
a study on treatment of latent TB among North-American
Latino adolescents [38]. Self-report measures are easy to
obtain, allow for discussion of obstacles to adherence, are
inexpensive and not as labour intensive as some other
adherence measures. In our study, unlike most clinical set-
tings, dedicated study pharmacists were responsible for
assessing adherence by pill count, whilst study doctors/
nurses were responsible for assessing self-report. There-
fore, contrary to what would be expected in an opera-
tional setting, our clinical staff preferred pill counts to self-
reports. Furthermore, caregiver self-reports were often dif-
ficult to obtain as the children arrived for study visits with
a variety of caregivers, many of whom could not provide
information on how medication had been taken in the
previous week. Another practical obstacle to measuring
adherence encountered by our staff, which may be unique
to our setting, was the loss of medicine and diaries in
shack fires (fires in informal settlements, usually originat-
ing in dwellings where paraffin stoves or open fires are the
only sources of heat and energy).
There are three major limitations to our study. First, our
main analysis is based on an adherence measure which
was only initiated after some children had already been
lost to follow up. Attrition is not unexpected in clinical tri-
als and yet it represents an extreme form of non-adher-
ence. Thus, it is possible that we overestimated the overall
adherence, as initial defaulters were not accounted for in
the analysis. However, as attrition rates were similar in the
two prophylaxis groups, this should not influence the
comparison between daily and intermittent dosing. Sec-
ondly, our estimates are based on measures known to
overestimate adherence. However, the measures had a rel-
atively high degree of concordance and our findings are in
keeping with the reports on adherence to HAART in HIV-
infected children in similar settings. Lastly, we report
adherence as measured in a clinical trial setting. Adher-
ence in clinical trial settings is necessarily higher than in
operational settings. As clinical trials require informed
consent and often preliminary visits before study enrol-
ment, individuals most likely to be non-adherent may
well choose to not participate in the trial. Hence, adher-
ence among trial participants is not necessarily predictive
of the likely adherence to a similar intervention in the
general population. Furthermore, overburdened and
unsupported clinic staff members are less likely, and in
many cases simply unable, to provide vigilant adherence
support such as written or telephonic reminders, mealsBMC Medicine 2009, 7:67 http://www.biomedcentral.com/1741-7015/7/67
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and payment of transport costs. Such support, however, is
integral to a prospective study protocol. Patients are also
more likely to be subjected to long waiting times, inter-
rupted drug supplies and worse interpersonal experiences
with care providers in resource poor health care centres
outside of a study setting [39]. Yet many of these adher-
ence barriers are being addressed and successfully over-
come in the context of HIV and HAART [1,26]. Our study
suggests that, with adequate adherence support, high lev-
els of adherence to INH prophylaxis can be achieved
among selected HIV-infected children despite poor socio-
economic circumstances and a prolonged period of
prophylaxis.
Medication adherence among HIV-infected children has
been extensively studied in the context of HAART. Varia-
ble predictors of adherence have been reported in the lit-
erature, some seemingly inconsistent [40]. Although our
study was not primarily designed to evaluate adherence
predictors, we found two associations that might serve to
assist health-care workers in identifying children at higher
risk for non-adherence. Although adherence in young
children depends on the care-giver, age has often been
cited as an adherence predictor, with some studies finding
younger children to be more adherent and others report-
ing better adherence in older children [15,41-43]. Many
of these studies evaluate age as a continuous measure,
without differentiating between the different stages of
childhood development. In particular, most studies
include adolescents, who frequently struggle with adher-
ence in ways that are different to younger children [40].
Our study included mostly young children, with very few
adolescents. Differentiating between infants, toddlers and
pre-school children (> 4 years), we found a significantly
better adherence among the pre-school children. This may
partly be due to the fact that our study drug (INH/pla-
cebo) was administered in tablet form. Toddlers, and
especially infants, might easily reject not only the taste but
also the texture of crushed tablets. Furthermore, it is per-
haps easier to negotiate medication adherence in a verbal
child than in an infant or toddler. Unfortunately, child-
friendly medication in palatable syrup form remains una-
vailable in many resource-limited settings. The provision
of guidance to parents on sources of palatable, safe sub-
stances to disguise texture and flavour of life-saving med-
ication should be particularly focused on those with
infants and toddlers.
In contrast to a recent report on adherence to HAART
among children from a similar South African setting, we
did not find any association between adherence and
socio-economic factors such as access to water, electricity
or a flush toilet [28]. We did, however, find a strong asso-
ciation with our indicator for crowding (that is, the
number of people per house). A South African study eval-
uating intermittent versus daily chemotherapy for the
treatment of childhood TB similarly found a significant
association between household crowding and adherence,
with children from crowded homes achieving a poorer
adherence [15]. As children depend largely on caregivers
for the administration of treatment, caregiver characteris-
tics are important determinants of adherence [40,42].
Studies from North America have described improved
adherence where primary caregivers were not the biologi-
cal parents, possibly relating to parents' emotions regard-
ing their own HIV status [40,44]. However, caregiver
characteristics and their impact on adherence are complex
and it is not possible to generalise between different cul-
tural settings. In contrast to reports from industrialized
settings, adherence was better among Togolese children
whose primary caregivers were their biological parents
[45]. A study from South Africa noted misunderstandings
between multiple caregivers to be a commonly cited rea-
son for non-adherence to HAART [27]. The association we
found between crowding and non-adherence might relate
to unmeasured caregiver characteristics, such as having
multiple caregivers, rather than to general socio-economic
circumstances. Certainly, the complex role of caregiver
characteristics in HIV-related paediatric adherence must
be explored and refined in the African context. Household
size is easily determined and could be a useful tool in
assisting health care workers in similar settings to identify
children who may be at a higher risk for non-adherence.
Conclusion
To achieve the Millennium Development Goal 6, target 8
(that is, to halt and reverse TB incidence by 2015), HAART
and TB prophylaxis must be affordable and accessible to
HIV-infected adults and children in resource-limited set-
tings, including sub-Saharan Africa [23]. We report excel-
lent adherence to three times per week INH and conclude
that intermittent dosing could be considered as a more
affordable measure for the provision of TB prevention to
HIV-infected children.
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